NeuroSense Therapeutics Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer’s Disease Biomarkers

Reuters10-06

NeuroSense <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer's Disease Biomarkers

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has announced new findings from its Phase-2b PARADIGM clinical study evaluating PrimeC in Alzheimer's disease. According to the company, analysis of plasma samples demonstrated that PrimeC significantly reduced several microRNAs associated with Alzheimer's disease pathology, including miR-146a-5p, miR-21-5p, miR-let-7a-5p, and miR-let-7e-5p, as measured by change from baseline. These microRNAs are linked to neuroinflammation, amyloid and tau pathology, and synaptic dysfunction. No significant changes in these biomarkers were observed in the placebo group. The results have already been presented by NeuroSense and are expected to inform the design of future Alzheimer's disease studies, while the company continues to advance PrimeC's Phase 3 readiness program in ALS.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN90811) on October 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2573772086?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573772086","market":"nz","top_or_hot":-1,"title":"NeuroSense Therapeutics Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer’s Disease Biomarkers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NeuroSense <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer's Disease Biomarkers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has announced new findings from its Phase-2b PARADIGM clinical study evaluating PrimeC in Alzheimer's disease. According to the company, analysis of plasma samples demonstrated that PrimeC significantly reduced several microRNAs associated with Alzheimer's disease pathology, including miR-146a-5p, miR-21-5p, miR-let-7a-5p, and miR-let-7e-5p, as measured by change from baseline. These microRNAs are linked to neuroinflammation, amyloid and tau pathology, and synaptic dysfunction. No significant changes in these biomarkers were observed in the placebo group. The results have already been presented by NeuroSense and are expected to inform the design of future Alzheimer's disease studies, while the company continues to advance PrimeC's Phase 3 readiness program in ALS.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NRSN\">Neurosense Therapeutics Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN90811) on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NeuroSense Therapeutics Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer’s Disease Biomarkers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuroSense Therapeutics Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer’s Disease Biomarkers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-06 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NeuroSense <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer's Disease Biomarkers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has announced new findings from its Phase-2b PARADIGM clinical study evaluating PrimeC in Alzheimer's disease. According to the company, analysis of plasma samples demonstrated that PrimeC significantly reduced several microRNAs associated with Alzheimer's disease pathology, including miR-146a-5p, miR-21-5p, miR-let-7a-5p, and miR-let-7e-5p, as measured by change from baseline. These microRNAs are linked to neuroinflammation, amyloid and tau pathology, and synaptic dysfunction. No significant changes in these biomarkers were observed in the placebo group. The results have already been presented by NeuroSense and are expected to inform the design of future Alzheimer's disease studies, while the company continues to advance PrimeC's Phase 3 readiness program in ALS.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NRSN\">Neurosense Therapeutics Ltd</a>. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN90811) on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRSN","symbol_name":"Neurosense Therapeutics Ltd","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL50KBy6:1","article_id":"2573772086","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573772086","pubTimestamp":1759755657,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NeuroSense Therapeutics Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer's Disease Biomarkers. NeuroSense Therapeutics Ltd.  has announced new findings from its Phase-2b PARADIGM clinical study evaluating PrimeC in Alzheimer's disease. According to the company, analysis of plasma samples demonstrated that PrimeC significantly reduced several microRNAs associated with Alzheimer's disease pathology, including miR-146a-5p, miR-21-5p, miR-let-7a-5p, and miR-let-7e-5p, as measured by change from baseline. These microRNAs are linked to neuroinflammation, amyloid and tau pathology, and synaptic dysfunction. No significant changes in these biomarkers were observed in the placebo group. The results have already been presented by NeuroSense and are expected to inform the design of future Alzheimer's disease studies, while the company continues to advance PrimeC's Phase 3 readiness program in ALS.Disclaimer: This news brief was created by Public Technolog","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRSN":"Neurosense Therapeutics Ltd","BK4139":"生物科技"},"translate_title":"NeuroSense Therapeutics宣布PrimeC的积极2b期结果，显示阿尔茨海默病生物标志物显著减少","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRSN":0.9},"content_text":"NeuroSense Therapeutics Announces Positive Phase 2b Results for PrimeC, Showing Significant Reduction in Alzheimer's Disease Biomarkers\n    \n\n        NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has announced new findings from its Phase-2b PARADIGM clinical study evaluating PrimeC in Alzheimer's disease. According to the company, analysis of plasma samples demonstrated that PrimeC significantly reduced several microRNAs associated with Alzheimer's disease pathology, including miR-146a-5p, miR-21-5p, miR-let-7a-5p, and miR-let-7e-5p, as measured by change from baseline. These microRNAs are linked to neuroinflammation, amyloid and tau pathology, and synaptic dysfunction. No significant changes in these biomarkers were observed in the placebo group. The results have already been presented by NeuroSense and are expected to inform the design of future Alzheimer's disease studies, while the company continues to advance PrimeC's Phase 3 readiness program in ALS.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN90811) on October 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2573772086","isCrawlerRequest":true}